Sarepta’s Duchenne gene therapy gets off to a strong start in sales, as future lies in limbo
Sarepta Therapeutics said it brought in $69 million in sales from its Duchenne muscular dystrophy gene therapy in the first few months the treatment has …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
